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Abstract 
Background: Enhancement of functional ambulation is a key goal of rehabilitation for children with cerebral palsy 
(CP) who experience gross motor impairment. Physiotherapy (PT) approaches often involve overground and tread-
mill-based gait training to promote motor learning, typically as free walking or with body-weight support. Robotic-
assisted gait training (RAGT), using a device such as the Lokomat®Pro, may permit longer training duration, faster 
and more variable gait speeds, and support walking pattern guidance more than overground/treadmill training to 
further capitalize on motor learning principles. Single group pre-/post-test studies have demonstrated an associa-
tion between RAGT and moderate to large improvements in gross motor skills, gait velocity and endurance. A single 
published randomized controlled trial (RCT) comparing RAGT to a PT-only intervention showed no difference in gait 
kinematics. However, gross motor function and walking endurance were not evaluated and conclusions were limited 
by a large PT group drop-out rate.
Methods/design: In this two-group cross-over RCT, children are randomly allocated to the RAGT or PT arm (each with 
twice weekly sessions for eight weeks), with cross-over to the other intervention arm following a six-week break. Both 
interventions are grounded in motor learning principles with incorporation of individualized mobility-based goals. Ses-
sions are fully operationalized through manualized, menu-based protocols and post-session documentation to enhance 
internal and external validity. Assessments occur pre/post each intervention arm (four time points total) by an independ-
ent assessor. The co-primary outcomes are gross motor functional ability (Gross Motor Function Measure (GMFM-66) and 
6-minute walk test), with secondary outcome measures assessing: (a) individualized goals; (b) gait variables and daily 
walking amounts; and (c) functional abilities, participation and quality of life. Investigators and statisticians are blinded to 
study group allocation in the analyses, and assessors are blinded to treatment group. The primary analysis will be the pre- 
to post-test differences (change scores) of the GMFM-66 and 6MWT between RAGT and PT groups.
Discussion: This study is the first RCT comparing RAGT to an active gait-related PT intervention in paediatric CP that 
addresses gait-related gross motor, participation and individualized outcomes, and as such, is expected to provide 
comprehensive information as to the potential role of RAGT in clinical practice.
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Background
The maintenance and enhancement of walking abilities 
is an important focus of rehabilitation for children with 
cerebral palsy (CP) in order to promote the physiological, 
functional and social benefits associated with ambula-
tion (Stuberg 1992; Eisenberg et al. 2009; McKeever et al. 
2013). CP is the most common cause of childhood physi-
cal disability (Oskoui et  al. 2013) involving heterogene-
ous motor impairments caused by damage to the fetal 
or developing brain. Approximately 50% of children with 
CP require only orthoses or minimal assistive devices for 
independent mobility (i.e., Levels I and II of the Gross 
Motor Function Classification System [GMFCS]), while 
those in GMFCS Levels III and IV need extensive brac-
ing and walkers or wheelchairs to move short and/or long 
distances (Palisano et al. 2008). Moreover, while the neu-
rological damage is non-progressive in CP, walking skills 
tend to degrade with growth and age for those in GMFCS 
levels III and IV (Hanna et al. 2009) leading to increased 
reliance on non-ambulatory mobility options for effi-
ciency and ease (Bottos and Gericke 2003).
Although wheelchair use does not necessarily lead to 
physiological or anatomical deterioration (Bottos et  al. 
2001), the benefits of standing and walking may include 
enhanced cardiovascular fitness (Park et al. 2001; Bjorn-
son et  al. 2007), functional gains (Strifling et  al. 2008; 
Eisenberg et  al. 2009) and greater involvement in social 
roles (Lepage et al. 1998). Furthermore, decreased stand-
ing time reinforces sedentary behaviours in children 
with CP (Verschuren et  al. 2014), potentially increasing 
risk of comorbidities and premature mortality as seen in 
adults (Peterson et al. 2013). Beyond the health benefits, 
many families and clinicians emphasize walking because 
of the dominant societal beliefs that walking holds sym-
bolic value associated with ‘normalcy’ and reduction of 
the social stigma of disability (Gibson et al. 2012). Com-
bined with the evidence of positive health outcomes, 
these strong values result in extensive use and develop-
ment of physiotherapy (PT), orthopaedic and medical 
interventions that focus on walking (Novak et al. 2013). 
However, the recent emergence of technologically-based 
walking interventions has been criticized because of the 
increased focus on ‘normalcy’ (Phelan et al. 2014), high-
lighting that persistent efforts towards walking may limit 
time for other childhood activities and not increase par-
ticipation (Wiart 2011). In light of these pros and cons, it 
is important that rehabilitation practitioners seek better 
understanding of the impact of gait therapies and fami-
lies’ values related to walking, especially as compelling 
high technology options such as RAGT become more 
available (Phelan et al. 2014).
Over the last decade, therapy emphasis for children 
with CP has shifted from being largely impairment-based 
(i.e., strength training and range of motion work) to 
focusing on activity and participation, with incorpora-
tion of motor learning principles (Park and Kim 2013). 
These principles include high repetition and active par-
ticipation of the learner to promote neuroplasticity and 
skill acquisition (Levac et  al. 2009). In the context of 
walking-focused therapies, technology can capitalize on 
motor learning principles (Schindl et al. 2000). For exam-
ple, partial body-weight supported treadmill training 
(PBWSTT) systems extend the opportunity for repeti-
tive gait training to children who have lower tolerance 
for independent ambulation (GMFCS Levels III and IV) 
(Palisano et  al. 2008), supporting a focus on quality of 
gait and walking experience (motor learning aspects), as 
well as on walking endurance. Although PBWSTT results 
in improvements of time-distance aspects of gait and 
gait-related functional abilities for children in GMFCS 
II–IV (Willoughby et  al. 2009; Zwicker and Mayson 
2010; Bar-Haim et al. 2010; Johnston et al. 2011; Chrysa-
gis et al. 2012), the extensive manual assistance required 
for those in GMFCS III–IV often makes it difficult to 
use. Functional electrical stimulation (FES) devices can 
be used to stimulate muscle activation, however these 
devices typically target one muscle to support move-
ment of one joint (Pool et al. 2014). Many children with 
CP require multi-joint assistance for repetitive gait train-
ing. Robotic-assisted gait training (RAGT) devices, such 
as the commercially available Lokomat®Pro (Hocoma 
AG, Switzerland, www.hocoma.com), were designed to 
address these physical limitations through use of robotic 
leg orthoses to guide leg movement, and have been 
reported to be at least as efficacious as manually assisted 
PBWSTT (Tefertiller et al. 2011).
There is strong evidence of improved functional out-
comes following RAGT in adults with spinal cord injury 
and stroke, including increased gait speed and endur-
ance in the 6-minute walk test (Tefertiller et  al. 2011), 
but gains are not always superior to traditional PT out-
comes (Dobkin and Duncan 2012). In children and youth 
with CP, knowledge about the impact of RAGT is limited 
(Castelli 2011). One-group studies have demonstrated 
an association between RAGT training and moderate 
to large improvements in gross motor skills, gait veloc-
ity and endurance (Meyer-Heim et al. 2007, 2009; Koenig 
et  al. 2008; Brütsch et  al. 2010; Drużbicki et  al. 2010; 
Borggraefe et  al. 2010a, b; Pajaro-Blazquez et  al. 2013; 
Schroeder et al. 2014b) as well as improvements in per-
formance and satisfaction of activities of daily life/par-
ticipation (Schroeder et al. 2014a, b). A single published 
randomized controlled trial (RCT) comparing Lokomat 
training to a PT-only intervention showed no difference 
in gait kinematics, yet gross motor function and walk-
ing endurance were not evaluated and conclusions are 
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further limited by a greater than 50% drop-out rate in 
the control group (Druzbicki et al. 2013). At the time of 
designing this study and receiving funding, only one RCT 
comparing Lokomat training to a waitlist control group 
was active (clinicaltrials.gov). A summary of the paediat-
ric studies and key results is provided in Additional file 1.
Stronger evidence is required to provide the neces-
sary understanding of the role and potential of RAGT 
as a clinical therapy for children with CP (Zwicker and 
Mayson 2010; Druzbicki et al. 2013; Aurich Schuler et al. 
2015). To address this knowledge gap, we developed an 
RCT with a cross-over design to compare a program of 
RAGT using the Lokomat to a gait-related PT program in 
children with CP in GMFCS Levels II and III. These chil-
dren are expected to have primary goals that are walking-
based, and their existing ability to ambulate permits use 
of gait-related therapeutic content in each intervention 
arm. The chosen outcome measures extend beyond the 
GMFM and assessment of gait, and incorporate indi-
vidualized goals as well as activity and participation out-
comes. By controlling for concurrent PT, co-intervention 
concerns arising from previous studies of RAGT are 
reduced. Further, an acknowledged limitation of RAGT 
is that participants can passively move through a stand-
ardized gait cycle (Koenig et al. 2011) and if sessions are 
not designed to be interactive, the benefits may be infe-
rior to an active PT program. Thus both Lokomat and PT 
intervention protocols used in this study are grounded in 
motor learning theory, following principles to optimize 
learning and promote active engagement of the partici-
pant by progressively increasing the challenge, introduc-
ing variability, promoting high repetition, and practicing 
activities that are meaningful to the child by specifically 
targeting the child’s goals (Levac et al. 2009). Intervention 
protocols are fully operationalized and will be reported 
in detail (a critical aspect of external validity) to provide 
clinically applicable information not included within 
Lokomat study publications thus far.
Methods
The study is a two group (Lokomat intervention versus 
gait-related PT intervention), randomized cross-over 
trial (Senn 2002) with a six-week break between the two 
intervention arms (A and B) at the time of cross-over. 
Assessments are done at four time points: baseline pre-
intervention A, post-intervention A; baseline pre-inter-
vention B, and post-intervention B. CONSORT (Schulz 
et al. 2010) and SPIRIT (Chan et al. 2013) guidelines were 
taken into account in the design of the trial protocol, and 
the CONSORT diagram (modified for cross-over tri-
als) is provided in Fig.  1. Assessments and intervention 
sessions are all conducted at Holland Bloorview Kids 
Rehabilitation Hospital, Toronto, Canada. Full ethical 
approval was obtained from the Research Ethics Board 
(REB) at Holland Bloorview. This REB must approve any 
potential protocol amendments, and regulate whether 
amendments must be communicated to participants and 
families.
Further details and rationale for the design decisions 
are provided in the “Design” section below.
Study aims and hypothesis
The primary aim of the study is to determine the 
impact on gait-related gross motor skills of a gait train-
ing program using a robotic-assisted gait trainer (the 
Lokomat®Pro) compared with a gait-related physiother-
apy (PT) program for children in GMFCS Levels II and 
III. The primary hypothesis is that children receiving the 
Lokomat intervention will improve more on the GMFM-
66 and 6-minute walk test (6MWT) than those in the 
gait-related PT program.
The secondary objective is to evaluate the compara-
tive impact of Lokomat training and gait-related PT on: 
(a) individualized walking/gross motor based goals; (b) 
the amount/location of walking the child does each day 
(environmental context and season considered); (c) par-
ticipation in activities and (d) health-related quality of 
life.
Study sample and recruitment
The study aims to enrol 40 children with CP (ages 
5–12 years) as follows: (a) 20 children in GMFCS Level II 
who have walking limitations but ambulate without a gait 
device or crutches or canes for most distances; and (b) 20 
children in GMFCS Level III who have a greater extent 
of walking limitation and use walkers or wheelchairs for 
short to long distances (Russell et al. 2000).
Inclusion criteria
Children are: (a) age 5 to12 years inclusive; (b) in GMFCS 
Levels II or III; (c) able to follow testing instructions, and 
participate in a minimum of 30 min of active PT; (d) able 
to reliably signal pain, fear and discomfort; (e) have pas-
sive range of motion (ROM) of hips and knees within 
minimum range requirement for Lokomat (hip and knee 
flexion contracture ≤10°, and knee valgus ≤40°); and (d) 
able to commit to attendance of twice weekly for eight 
weeks (to support the primary efficacy analysis).
Exclusion criteria
In addition to all relevant criteria outlined in the Lokomat 
manufacturer’s manual (Hocoma AG, Switzerland, www.
hocoma.com), children are excluded if they have: (a) hip 
instability/subluxation >45%; (b) orthopaedic surgery 
within the last 9 months (muscle) or 12 months (bone); 
(c) Botulinum toxin-A (BTX-A) injections to lower limb 
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in the last 3 months; (d) inability to discontinue BTX-A 
for period of 6  months (during trial) due to concerns 
about ROM or pain; (e) any weight bearing restrictions; 
(f ) seizure disorder that is not controlled by medication 
(if on medication, must not have had a seizure in the last 
12 months); (g) open skin lesions or vascular disorder of 
lower extremities; or are: (h) not able to co-operate or be 
positioned adequately within the Lokomat as shown dur-
ing the two Lokomat fitting/acclimatization sessions; (i) 
not prepared or unable to discontinue a regular therapy 
Fig. 1 Flowchart of enrolment according to CONSORT guidelines. *CDP: Child Development Program at Holland Bloorview Kids Rehabilitation 
Hospital, Toronto, Canada. **Baseline Assessments occur <14 days prior to start of intervention arm. ***Post-Intervention sessions occur <7 days 
after end of intervention arm
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intervention during the course of the trial; (j) involved in 
another intervention study.
Design
This study uses a cross-over design to compare the two 
different therapy intervention programs: robotic assisted 
gait training (Lokomat) versus gait-focused PT (see 
Fig.  1). The order of treatment (Lokomat or PT first) is 
designated by random assignment. Children cross-over 
to the second intervention arm following a six-week 
non-treatment break between interventions. The second 
intervention arm begins after a second baseline assess-
ment completed at the end of the break to re-establish 
the child’s abilities. The use of a cross-over design helps 
to reduce the impact of confounding variables outside 
of the control of the study itself, since each cross-over 
participant acts as his/her own control (i.e., reduces 
between subject variation) (Senn 2002). Cross-over 
designs are also more efficient than standard RCTs or 
repeated measure designs, requiring fewer participants 
(Louis et al. 1984). While there may be concern that the 
extended length of involvement in the trial to complete 
both phases may be an obstacle for enrolment or adher-
ence, cross-over designs have been successfully employed 
in CP and Lokomat research (McNee et  al. 2007; Mayr 
et al. 2007). Furthermore, the opportunity to receive both 
intervention arms and be assured access to the Lokomat 
is thought to outweigh any perceived burden of the time 
commitment (Law et al. 1997).
Each intervention is given twice weekly for a total of 16 
sessions over a targeted treatment period of 8 weeks. This 
training frequency mirrors a standard clinical PT treat-
ment block. A maximum of 10 weeks is targeted to keep 
the dose as close to twice a week as possible while taking 
into account the occasional need to miss a session due 
to illness, vacation, and other unavoidable interruptions. 
The total number of sessions is similar to trials in which 
Lokomat effectiveness was demonstrated (Koenig et  al. 
2008; Borggraefe et  al. 2010a, b; Meyer-Heim and van 
Hedel 2013; Schroeder et al. 2014a, b) while a chief differ-
ence is the total duration of the treatment period, in that 
other Lokomat trials have used a short intensive burst of 
therapy (e.g., 15 treatments over three weeks). Our con-
cern from a motor learning and assimilation standpoint 
is that a short burst may be insufficient time for the child 
to develop and integrate new skills gained through train-
ing into their daily life.
Children are required to discontinue regular PT inter-
ventions prior to the first baseline assessment and to 
abstain from starting any other PT during the trial to 
reduce the chance of confounding effects associated 
with any previous or concurrent treatment. The child 
is allowed to continue any existing program of soft tis-
sue stretches and/or basic walking and standing, but 
their clinical physiotherapist (PT), or other clinician, is 
asked not to alter the programs during the course of the 
study. Activities are monitored at the start of each inter-
vention session (Lokomat or PT), when the child and 
parent are asked by the study PT about any other gross 
motor-based treatments and physical activity they did 
since the last session. These physical activity descrip-
tions are documented in the child’s session log. The study 
PT is required to alert the research assistant (RA) to any 
potential co-interventions. Subsequently, the RA calls the 
parent to ask them to put any activities on hold that are 
judged to be walking-related co-interventions.
During the six-week break that occurs before crossing 
to the other intervention arm, the child is allowed to con-
tinue their existing regimen of soft tissue stretches and 
any basic walking/standing home program they had been 
given prior to the trial, but asked not to embark on any 
other new therapy. The RA phones the parent mid-way 
through this phase to check for any treatments that the 
child may have started/resumed. A request to discon-
tinue any added treatment may be made by the RA after 
discussion with the co-Principal Investigators (co-PIs) if 
it appears to be a gait-related co-intervention (i.e., a pos-
sible confounder). While the six weeks between the two 
intervention arms is not a true wash-out period (since 
effects of rehabilitation are not expected to be reversible 
when therapy is withheld), it does give a time break for 
families between the two phases. A new baseline is estab-
lished before starting the second intervention to ensure 
intervention effects are isolated for analysis (Mayr et al. 
2007).
Study enrolment
Invitation letters are sent to parents of eligible partici-
pants registered in the Child Development Program 
(CDP) at Holland Bloorview Kids Rehabilitation Hospital, 
a program with a large CP population that will support 
achievement of target enrolment numbers. If interested, 
parents complete a basic screening over the phone with 
the RA followed, if suitable, by a more detailed eligibility 
questionnaire. An eligibility form is also sent, with par-
ents’ permission, to the child’s clinicians to ensure there 
are no concerns with study participation and use of the 
Lokomat. The second step for children who meet these 
initial criteria is a formal screening assessment. The co-
PIs then review findings with the assessor and confirm 
with the family whether the child is eligible for the study 
based upon these findings (see Fig.  1 for details). The 
RA obtains written informed consent from participants 
and parents at two time points: prior to study screening 
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assessment and, if screening criteria are satisfied, prior to 
participating in the intervention. Assent is obtained from 
children incapable of providing independent consent.
Randomisation
Children who meet the eligibility criteria and pass the 
screening assessment are assigned a study ID number, 
and then attend their baseline assessment. Following 
the baseline assessment, the child is allocated to start in 
either the Lokomat or PT intervention phase via a pro-
cess of random assignment using a computer gener-
ated random numbers system. The assignment scheme 
was prepared at the start of the study by a non-study 
RA, using a stratified randomisation process (age and 
GMFCS level) that employed mixed allocation blocks 
of 4 and 6 children. By the end of the trial, this system 
will ensure that the number and age/GMFCS balance of 
participants who start in the Lokomat and PT interven-
tion groups will be even. Management of the randomisa-
tion process by a non-study RA through the entire study 
allows the study investigators to remain blinded to the 
scheme, thereby eliminating allocation bias. Participants 
are informed of the intervention order by the study RA.
Blinding
It is not possible to blind the parent or child or study PT 
to the study interventions. The study’s PT assessors (a 
separate group from the treating study PTs) are blinded 
to the child’s treatment arm. The same assessor evaluates 
the child at each of the baseline and follow-up sessions. 
The inability to guarantee full success of the blinding 
is due to overlapping clinical and research treatment/
assessment areas, and the possibility that despite asking 
them not to, children and parents might inadvertently 
comment on their treatment session experiences to the 
assessor. Given the strength of objectivity of the out-
come measures at single points in time however, concern 
about the impact of knowledge of group membership is 
low (Wood et al. 2008). More importantly, to prevent any 
influence of knowledge of previous results on current 
assessments, prior assessment data are not available to 
the assessor at any of the follow-up assessments. Finally, 
to verify unbiased scoring on the key observational meas-
ures (GMFM-66, 6MWT, Challenge  Assessment, Timed 
Up and Go), a non-study RA will select a random sample 
of 20% of the assessment video-recordings to be scored 
by an independent PT assessor blinded to the assess-
ment’s order in the evaluation sequence.
The study statistician is blinded to group allocation 
in all analyses. All data are stored in a secure database 
using Research Electronic Data Capture (REDCap) (Har-
ris 2012), and are entered by the study RA. Data are de-
identified using participant study codes. Access codes 
will be given to the co-PIs for select data sections (i.e., 
demographics, individualized goals [for purposes of 
fidelity monitoring], treatment adherence, adverse event 
tracking), but lack of access to other outcome areas of the 
database supports PI blinding to the results during the 
trial. This is important to keep study communications 
and decisions free from the influence of knowledge of 
outcomes.
Study interventions
In both the PT and Lokomat intervention arms, the study 
PTs have the opportunity to look at the baseline assess-
ment data acquired prior to the first Lokomat or PT ses-
sion to ensure sufficient clinical understanding of the 
child to be able to make suitable treatment and goal deci-
sions. Within each intervention arm, a study treatment 
log of each session is kept for every participant. Each ses-
sion is fully documented by the study PT on log sheets 
that require detailed and open disclosure of all activities 
performed. This log is available to the study PT at each 
session to permit reference back to previous sessions and 
support progression. The logs are checked at bi-weekly 
intervals by the study RA so that any fidelity issues can be 
addressed in subsequent sessions. Following completion 
of the intervention arm, completed forms are removed 
and replaced by a new set of treatment logs. The study 
RA will also monitor session attendance to problem solve 
any issues promptly.
The information recorded in these session logs will 
allow us to fully operationalize all of the aspects of the 
treatment approaches at the end of the study (an impor-
tant external validity consideration). The within-session 
documentation process is also expected to optimize 
adherence of the study PT to the intervention proto-
cols (treatment fidelity). Furthermore, two of the child’s 
Lokomat and PT sessions are filmed to permit evaluation 
at the end of the study of the extent and type of motor 
learning strategy use within the interventions, using the 
Motor Learning Strategy Rating Instrument (MLSRI) 
developed by Levac et al. (2009), and validated by Kamath 
et al. (2012) at our centre.
Lokomat intervention protocol
At the start of the child’s Lokomat intervention block, 
there are two initial fitting/acclimatization sessions, 
and then 16 twice-weekly Lokomat sessions over an 
8- to 10-week period. Fitting the child and acclimatiza-
tion on the Lokomat is done as outlined in the Lokomat 
User Manual (Hocoma AG, Switzerland, www.hocoma.
com). The goal is to ensure that the child is comfort-
able in the exoskeleton (e.g., right fit of straps and cuffs, 
alignment set within a tolerable range of movement) as 
well as on the treadmill mechanism, and that the child 
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is able to follow the PT’s instructions and to indicate 
any discomfort. The Lokomat intervention is designed 
as a standardized protocol, and the content and method 
for progressing settings on the Lokomat are outlined in 
Additional file 2. The home program component is lim-
ited to basic stretching, strengthening exercises and/or 
walking practice that the child was on pre-study.
The Lokomat treatment sessions start with 10–20 min 
on the Lokomat, increasing as tolerated within three ses-
sions to the 30 min maximum target time for this study 
(Mayr et  al. 2007). Four parameters are adapted to the 
ability, strength, and endurance of the child: body weight 
support provided; walking duration; ambulation veloc-
ity; and guidance force provided to each leg. Guidelines 
for parameter adjustments are provided in Additional 
file 2 along with suggested protocols in the Lokomat User 
Manual, which will inform the setting changes the thera-
pist makes throughout the session. These adjustments 
will be made to target the child’s gait goals. If a child is 
unable to keep up with any of the progressions, adjust-
ments will be carried out to a lesser extent or reversed. 
From a content perspective, the motor-learning based 
protocol follows both the Lokomat guidelines for encour-
aging lower limb selective muscle/joint activation and 
motor learning, and also includes a listed series of upper 
body tasks that can be done while walking (e.g., throw-
ing a ball, hitting an overhead object) to encourage multi-
tasking and improved posture. Use of Lokomat virtual 
reality games and provision of visual biofeedback are also 
permitted to promote engagement and feedback. Each 
session is followed by 5 min of rest before a 5-min over-
ground gait training session to reinforce the Lokomat 
session gait focus outside of the Lokomat.
Information on the body weight support provided, 
walking duration, ambulation velocity, and guidance 
force provided to each leg are recorded in the child’s 
treatment log as they occur during the session along with 
details of any breaks or “free rides” (time spent passively) 
in the Lokomat. In keeping with the principles of motor 
learning, the goal is to optimize active participation and 
keep passive walk time to a minimum. The Lokomat 
computer also continuously tracks all of the settings used 
throughout the session and provides setting-based infor-
mation related to any safety stops initiated by the Loko-
mat. Safety stops occur in reaction to movement forces 
from the child that are outside of the parameter bounda-
ries of the Lokomat for that child.
Gait‑related PT intervention protocol
This intervention has been created as a motor-learning 
outpatient program that requires intensive PT guidance, 
coaching and therapy equipment. At the start of the 
child’s PT intervention block, there is one acclimatization 
session to introduce the child to the PT gym equipment 
and surroundings, and then 16 twice-weekly PT sessions 
over an 8- to 10-week period. Each PT session consists 
of 35 min of active treatment with 10 additional minutes 
of introduction and wrap-up conversation, which paral-
lels the 30 min of Lokomat walking, 5 min of overground 
walking and similar period of conversation times in the 
Lokomat group.
The PT session follows a manualized protocol created 
specifically by Holland Bloorview Child Development 
Program PTs in conjunction with study co-PIs (see Addi-
tional file  3). This GMFCS level-specific PT program is 
grounded in current evidence-informed clinical prac-
tice. From a content perspective, it is menu-based with 
delineation of key categories of treatment focus. Treat-
ment components are provided within each of these cat-
egories. Virtual reality (VR) interventions are permitted 
as these are now a standard part of PT treatment (Wang 
and Reid 2011). Treadmill training is allowed to a maxi-
mum of 10  min, but body weight support is not per-
mitted as per design in Mayr et  al. (2007). This avoids 
potential contamination through introducing elements of 
the weight-relieving and limb guidance gait component 
of the Lokomat protocol into the PT intervention. Other 
interventions to be avoided are those that are outside 
mainstream PT (e.g., Cuevos Medek, conductive educa-
tion techniques) or focus on changes to body structures 
(e.g., lower limb Botox, inhibitive casting, osteopathy, 
kinesiotaping).
The PT is at liberty within each session to choose 
treatment categories and components that link with the 
child’s goals (as documented at the start of the interven-
tion phase) and progress those goals as they see appro-
priate based on their clinical judgment. Each component 
that is given is recorded in the child’s treatment log at the 
end of the session along with the area of primary focus of 
the activity (chosen from a list of areas that include bal-
ance, strength, agility, gait quality, walking endurance, 
etc.), details of repetitions, equipment use or settings, 
and number of minutes spent on each activity. As with 
the Lokomat arm, the home program is limited to the 
basic stretching and strengthening exercises and walk-
ing practice that the child was on before they entered the 
study. For children who start in the PT arm, this will help 
to reduce the possibility of carryover of home treatment 
ideas from the PT intervention into the Lokomat phase 
(contamination).
Study intervention PTs
There are 12 paediatric PTs (all specialists in working 
with children with CP or brain injury) who were spe-
cially trained as described below to provide the Lokomat 
and PT interventions. Each child is assigned to a study 
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treatment team consisting of two PTs who share respon-
sibility for the twice-weekly treatment sessions. Use of a 
two-member intervention team is consistent with typical 
models of service delivery in which a PT and PT Assistant 
(PTA) share responsibility for a child’s treatment. This 
team approach also promotes adherence by permitting 
maximum scheduling flexibility for families from Mon-
day through Sunday, ensuring a spacing of two to three 
days between the twice-weekly sessions. The same two-
PT team is responsible for provision of therapy to the 
child across both intervention phases, providing a con-
stancy of rapport and interaction style between the PTs 
and child/parent across interventions. The advantages 
of this approach are likely to outweigh any intervention 
preference bias that might influence the actual treatment 
given. The consistency of treatment focus between PTs is 
enhanced through strict guidelines as to what treatment 
approaches may/may not be used, the menu-based and 
goal-directed intervention design, and the full documen-
tation of all session components. These standardization 
strategies are very important in the PT intervention given 
the greater latitude for individual PT treatment variation.
A PTA is present for the Lokomat therapy intervention 
arm to assist with child set up to optimize the speed of 
set up, and help with Lokomat setting changes as well as 
documentation of setting changes throughout the ses-
sion. The PTA is not present at the PT sessions unless the 
PT feels that one is required to ensure safety of the child 
in the walking-related activities. This additional use of 
the PTA is fully documented in the session log.
Training of study intervention PTs and PTAs
Lokomat intervention
Certification for Lokomat use involves an extensive 2-day 
training session led by a Hocoma Lokomat licensed 
trainer. The first day of training familiarizes the PTs with 
the Lokomat and allowed practice with each other. At the 
second training day, PTs practice children with CP. Cer-
tification follows practice sessions with each other and 
with several other children with CP who were already 
receiving Lokomat therapy at a local clinic and hence not 
eligible for this study. This training approach ensures suf-
ficient familiarity with the treatment progression proto-
col. Following approximately 3  months of practice, PTs 
attend a 1-day review session led by the same Hocoma 
licensed trainer. PTAs also attended the training sessions 
with the Hocoma trainer to learn the basic components 
of set-up of the child into the Lokomat orthosis. While 
they are not operating any of the robotic features of the 
Lokomat or altering any settings with the children, they 
do assist with the set-up and monitoring. Thus, it was felt 
that they needed to have a full understanding of the oper-
ation principles of the Lokomat.
Gait‑related PT Intervention
The treatments involved in the gait-related PT interven-
tion are a standard part of PT practice and the skills do 
not need to be taught. However, the process for selecting 
what is done from the study menu (specified within each 
of the GMFCS Levels) and treatment restrictions were 
covered in a 3-h orientation session led by the Co-PI 
(VW). PTAs are rarely involved in this arm, and when 
they are, it is to provide physical assistance. Thus, extra 
training is not required.
Outcome measures
The primary outcome measures selected directly reflect 
those used in previous Lokomat studies (i.e., GMFM-66, 
6MWT, Timed Up and Go and Canadian Occupational 
Performance Measure [COPM]) (Russell et al. 2000; Rus-
sell et al. 2013; Thompson et al. 2008; Williams et al. 2005; 
Law et al. 1990), and expand into other ICF areas includ-
ing movement quality (Quality FM, basic gait assess-
ment of spatiotemporal variables via electronic walkway 
and observational assessment) (Wright et al. 2008, 2014; 
Sorsdahl et  al. 2008), ROM and spasticity (Tardieu) 
(Scholtes et al. 2006), advanced gross motor skills (Chal-
lenge Assessment) (Wright et  al. 2012; Glazebrook and 
Wright 2014), functional abilities (i.e., PEDI Caregiver 
Assistance and ASK-30) (Haley et  al. 1992; Young et  al. 
2000), and participation/QOL (i.e., step activity moni-
tor, CAPE and KIDSCREEN) (King et  al. 2007; Ravens-
Sieberer et  al. 2007; Bjornson et  al. 2014). Collectively, 
these outcome measures provide comprehensive infor-
mation in areas of activity and participation in alignment 
with the WHO ICF framework (World Health Organiza-
tion 2001). Questionnaires are completed by the parent 
as well as the child if the child is 8 years or older. Each 
measure is used at each of the four assessment sessions. 
Personal motivation characteristics of the child (Dimen-
sions of Mastery Questionnaire [DMQ]) (Miller et  al. 
2014) are assessed at baseline.
The COPM is completed by the child and parent with 
the assessor at the end of the assessment session, focus-
ing on activity and participation goals. Since the child is 
not randomized to an intervention group until after the 
baseline assessment, these are goals that fit a gait-related 
functional mobility program generally and are not spe-
cific to the Lokomat or PT arms. This it is anticipated 
that these will be higher-level activity and participation 
related goals that are suitable to either intervention. Goal 
attainment scaling (GAS) (King et al. 2000) is done dur-
ing the first two intervention sessions by the study PT 
with the child/parent. Working from the COPM goals 
that were created at baseline by the PT assessor, the study 
PTs re-script these into measurable GAS goals that fit 
with the intervention (PT or Lokomat) and what they 
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learned about the child from review of their assessment 
results. This process allows the GAS aspect to be tied in 
directly to the perceived possibilities of the intervention 
arm, and fits with the specific outcome scaling process 
that is required within GAS, i.e., best suited to highly 
observable goal areas related to body structure and activ-
ity. Collectively it is hoped that the combined use of the 
COPM and GAS will provide a comprehensive evaluation 
of the extent and nature of goal accomplishments (GAS), 
as well as perceptions of performance abilities and satis-
faction with abilities (COPM).
Within sessions, measures to monitor pain (Wong-
Baker FACES® Pain Rating Scale) (Wong and Baker 
1988) and physiological effort (PCERT, heart rate) (Yell-
ing et al. 2002) are obtained by the study PT/PTA. At the 
end of each treatment arm enjoyment is obtained by the 
RA using a modified version of the PACES (Moore et al. 
2009) so that items evaluated make sense in the context 
of the Lokomat/PT sessions. A table of the measures 
(Table  1) provides details as to the GMFCS level each 
measure is linked with the format of administration 
(observational measure or questionnaire), time required 
and administration time points. Detailed information on 
each measure is provided in Additional file 4.
Training of the study assessors
The PT assessors have five to 20  years of experience in 
paediatric neurology and are familiar with the GMFM-
66 from clinical practice. Regardless, a group training 
session will be done with the GMFM-66 (barefoot and 
shoes/AFO versions). All assessors independently score 
three GMFM videotapes (a child in each of GMFCS I, 
II and III) from the co-PI (VW)’s GMFM video-train-
ing bank (including a section on recognizing/resolv-
ing GMFM test administration errors common to the 
GMFM’s Stand and Walk dimensions). All must achieve a 
criterion score of 80% accuracy (the same level used with 
the original GMFM criterion test). The 6MWT, ROM, 
Tardieu Scale and child-/parent-report-questionnaires 
(DMQ, ASK-30, CAPE, KIDSCREEN, PEDI) have simple 
administration requirements and do not require further 
testing beyond the initial group training session. During 
assessments, the assessor also works with the study RA 
to administer the 15-min gait assessment (time distance 
parameters of gait) using our Gait-Rite system and gait 
video.
Sample size
The study has been designed and powered to ensure ade-
quate sample size for the primary research questions and 
analysis of children in GMFCS Levels II and III. The start-
ing point for our sample size calculation consideration 
was a single group Lokomat study with a similar GMFCS 
sample and Lokomat use protocol in which the GMFM 
Stand and Walk mean scores changed by approximately 
5 points (SD change = 7) (Borggraefe et al. 2010b). Our 
study is powered to let us detect a difference between the 
two interventions of three points (SD  =  6: small effect 
size) on the GMFM-66, a magnitude of change that is 
considered to be a minimally clinically important differ-
ence (Oeffinger et  al. 2008) when evaluating benefits of 
treatment. The reason for a difference change target in 
our study is that we are comparing two active interven-
tions, each of which could result in positive change given 
the walking focus and boost for many of the children 
in therapy intensity. This sample size is also sufficient 
to handle the 6MWT comparisons and the small effect 
size observed by others in single group Lokomat studies 
in the 6MWT results (mean gains of 25 m [SD = 50 m], 
personal communication, Glenrose Hospital program, 
2012).
For crossover designs, sample size calculations that link 
with a matched pairs t test calculation are appropriate 
(Senn 2002). A paired t test is also the underlying basis 
for the more sensitive repeated measures ANOVA that 
we have chosen to use so that we can include a period 
effect within the analysis. With an alpha of 0.025, beta of 
0.20, and a detectable change score difference between 
intervention of thre points on the GMFM-66 (with an 
estimated SD of change of 6.0 points), a sample of 32 chil-
dren is required (Hintze 2001). We increased the sample 
requirement to 40 to account for a potential drop out/
protocol deviation rate of 20%. Sample calculation based 
on this generous drop-out rate will support the primary 
efficacy analysis that focuses only on the children who 
attend more than 70% of the sessions within one or the 
other intervention phase.
Analyses
Data entry forms were built for each measure in the study 
to correspond to the paper forms that the assessors used. 
REDCap (Harris 2012) requires outer limits for each 
value, and each paper data sheet is double entered for 
purposes of data verification process. Collectively these 
features optimize the data entry accuracy. Study data 
will be kept for seven years following conclusion of the 
trial, at which point data will be destroyed following REB 
requirements.
Descriptive statistics and graphic displays will be pre-
sented for all outcomes for the PT and Lokomat inter-
ventions (pre, post-test and change scores). Equivalence 
between baselineA and baselineB scores will be evaluated 
for each outcome; a t-test or Wilcoxon test will be used in 
this comparison as appropriate. The primary analysis will 
be for the pre- to post-test differences (change scores) of 
the GMFM-66 and 6MWT between groups. Assuming 
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normality of data, a repeated measures ANCOVA will be 
performed on GMFM-66 and 6MWT change scores to 
compare the effects of the Lokomat and gait-related PT 
interventions. The child’s relevant baseline score (base-
lineA/baselineB) will be used in the ANCOVA to increase 
analytic precision. The P value will be adjusted to 0.025 
to handle the expected high correlation between the 
GMFM-66 and timed walk. Evaluation of an intervention 
order effect (i.e., being the first or second treatment), as 
well as the interactions with intervention group will be 
built into this analysis (Senn 2002). Secondary sub-anal-
yses will be done in the same way within GMFCS II and 
Table 1 Table of measures
a Type of measure: O = PT observational assessment Q = interviewer introduced/guided questionnaire
Measure GMFCS level Type of measure/
respondenta
Time to complete
AT assessment Baseline 1 Post‑1 Baseline 2 Post‑2
Primary
GMFM-66 II & III O/PT with child 30–45 min x x x x




II and III) and with 
shoes/orthoses 
(GMFCS III)
II & III O/PT with child 30 x x x x
Timed Up and Go Test II and III O/PT with child 5 x x x x
Challenge Assessment II O/PT with child 30 x x x x
Quality FM II and III O–PT via GMFM video 30–60




tional gait scale 
(video rating)
II and III O/PT with child 15 x x x x
PEDI-functional skills II and III Q/parent 15 x x x x
ASK-30 II and III Q/child or parent 
proxy
15 x x x x
KIDSCREEN II and III Q/child or parent 
proxy
15 x x x x
CAPE II and III Q/child or parent 
proxy
15 x x x x
GAS and COPM II and III Q–child with parent 15 x x x x
Other






II and III Child wears at home 5 days
Done at sessions Before session Mid-point End of session Other time
 Rating of exertion 
(PCERT)
II and III Q/child 2 x x
 Heart rate II and III O/child 1 x x x
 L-WALK (Lokomat 
session distance)
II and III Lokomat system 
measure
N/A x
 Pain scale (FACES) II and III Q/child 2 x x
 PACES II and III Q/child 10 16th session
 Motor learning 
strategy rating 
instrument (MLSRI)
O/rater scores video 
of intervention 
session
30 Session week 2 and 7
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III subgroups to determine any differential response for 
GMFCS Level.
Due to the lack of expectation of return to baseline 
in the break period, a second analytic approach will be 
taken as well using a generalized estimating equation 
(GEE) adjustment for repeated measures within subjects 
analysis (Baker et  al. 2007). In this approach treatment 
effects are evaluated via regression analysis and the GEE 
method will allow the fit of two models. The first is for 
treatment effect, treatment-period effect, and differential 
carryover effect adjusting for the baseline scores, and the 
second is treatment effect and treatment-period effect 
with exclusion of any differential carryover effect. Fac-
tors hypothesized a priori to be associated with GMFM-
66 change score magnitude will be entered within this 
model using a forward stepwise regression procedure, 
e.g., age, GMFCS Level, motivation (DMQ) score, ASK 
baseline score.
Finally, a third approach will be taken if there is signifi-
cant evidence of a carryover effect and significant inter-
action effects. This will be to focus on the data from the 
first arm of the study, i.e., an ANCOVA adjusted for base-
line GMFM-66 change scores of just the first interven-
tion period (randomisation to either Lokomat or PT with 
20 children per group). This comparison in itself would 
have a power of about 0.60 for the GMFM-66 (with 
alpha = 0.025 and a medium effect size of 0.50).
A similar set of analytic approaches will be used for 
the secondary outcome measures (GMFM Stand and 
Walk, Timed Up and Go, walk velocity/step and stride 
length [from GAITRite], observational gait scale, aver-
age daily step counts [step activity monitor data], Quality 
FM, Challenge Assessment, ASK-30, PEDI Part II, KID-
SCREEN, COPM and GAS scores), using the baseline 
value of the measure of interest as a covariate within a 
MANCOVA procedure that will permit simultaneously 
handling of multiple secondary outcome measure change 
score evaluations. If both parent and child filled out the 
questionnaires (i.e., all children 8 years of age and up who 
were able to do so), the children’s data will be analysed 
as primary. Otherwise parent questionnaire data will be 
considered as primary. A comparison of child and parent 
questionnaire results will be done as a secondary analy-
sis via an ANOVA in which both single point in time 
(baseline) and change scores will be evaluated. ROM and 
Tardieu scores will be summarized in a simpler manner, 
using descriptive statistics and graphical presentations to 
illustrate scores in each phase. The power of all primary 
and secondary ‘no difference’ analyses will be determined 
post hoc.
The primary analysis will include all children who 
attended ≥70% of sessions for each intervention, and 
those who discontinued one or both interventions for a 
reason directly related to the study (e.g., excessive fatigue 
associated with participation or issues related to dislike 
of one or both interventions), or dropped out of the trial 
due to an intervention-associated injury. In the case of 
dropout due to study fatigue or dislike of the interven-
tion, a strong effort will be made to do a discharge assess-
ment at the time of withdrawal. In the case of injury, it 
may be possible to follow the child and evaluate some of 
the outcomes when the child is able (post-minor injury). 
If the physical assessment is not possible due to compro-
mised physical status, completion of the functional and 
participation measures may still be appropriate.
A second analysis will include all who adhered to 
≥50% of each intervention as well as those who discon-
tinued one or both interventions for reasons noted in 
the primary efficacy analysis. The third analysis will be 
an “intent to treat”, including the last available data from 
all participants regardless of level of adherence or reason 
for withdrawal. As outlined above, a strong effort will be 
made to do a discharge assessment at time of withdrawal. 
Demographic characteristics, baseline scores and change 
scores of these three adherence groups will be evaluated 
to determine any systematic differences in their charac-
teristics or outcomes.
Data from the session summary sheets will be com-
piled. Treatment categories, Lokomat parameter adjust-
ments, and session activities will be summarized through 
graphic and tabular summaries, and related descriptive 
information from therapists’ comments will be reported.
Adverse events (AE)
At the start, midpoint and end of each session heart rate 
is taken via pulse, and children are asked about any pain/
musculoskeletal issues using a visual analogue scale with 
pain ratings done as per the FACES® scale (Wong and 
Baker 1988) and a generic body diagram. All areas of the 
child’s skin that underlie the Lokomat straps and cuffs 
are checked by the study PT before and after every Loko-
mat session, with any areas of redness or skin breakdown 
marked on the body diagram. The expectation is that any 
areas of redness that occur during Lokomat therapy are 
transient and fully resolved by the next session. Failure 
to resolve between sessions requires adjustment of the 
straps or padding, realignment of the Lokomat set-up, 
use of skin protection tape, or withholding the next ses-
sion as appropriate. At the end of each session, the study 
PT enters all AE information noted at that session on 
an AE summary sheet and alerts the study RA to review 
the sheet. The RA and PI classify the event in terms of 
severity and attribution to the Lokomat or PT session, 
and determine necessary follow-up action according to a 
pre-set action protocol approved by the REB. This pro-
cess ensures that a prompt response, precautions and 
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reporting to the REB can be taken as required. All occur-
rences of open wounds or fracture are reported by the 
co-PIs within 24 h of the session to the REB with treat-
ment offered through Holland Bloorview. AEs are moni-
tored by a Safety Monitoring Committee (SMC) acting 
independently of the investigators and study funders. 
This SMC consists of a pediatrician, methodologist/
researcher, nurse, pediatric orthopaedic surgeon, PT, 
and a lay person. The SMC meets every four months 
to review any AE forms that have been filed since time 
of the previous meeting, or convenes a special interim 
meeting to review any event that required reporting to 
the REB. Early stopping of the trial will occur if a recom-
mendation to terminate the study is made by the SMC by 
majority vote. This may occur at any time, with decisions 
reported to the PI and REB by the SMC Chair immedi-
ately by telephone and email along with the reason for 
their decision. Withdrawals for reasons other than safety 
concerns will not be cause for study termination.
Discussion
This study’s comparison of the Lokomat intervention 
with a gait-related PT program is the first randomized 
trial that we are aware of in paediatric CP that incorpo-
rates a broad set of outcomes spanning the body struc-
ture/function, activity and participation aspects of the 
ICF-CY (World Health Organization 2007) as well as 
health-related quality of life (McDougall et al. 2010). To 
address co-intervention limitations in previous trials, 
RAGT is being delivered in isolation of other therapies. 
Group comparisons will be strengthened by having com-
parable group size, using a therapy intensity and dura-
tion designed to promote functional change with time for 
learning and transfer into daily life. The inclusion of indi-
vidualized goals and use of outcomes reflective of real-life 
activity and participation are unique to this study. The 
detailed reporting of intervention protocols and indi-
vidual goals will permit operationalization of therapy, 
extending potential benefits beyond the study cohort and 
informing transfer of the intervention approach into clin-
ical practice. The intervention session design is strength-
ened by the input and experience of participating PTs 
from the CDP clinical area.
The evaluation of an order effect (Lokomat or PT first) 
may provide important insights into clinical integration 
of Lokomat therapy with gait-related PT. For example, if 
overall gross motor outcomes are better when Lokomat 
therapy is given before a block of PT (e.g., quality gains 
on the Lokomat can be used to set the stage for func-
tional and participation gains with PT), this may be of 
value when determining the sequencing of blocks of ther-
apy to achieve gait-related goals.
If efficacious, RAGT holds promise for transforming 
treatment for children with CP and other neurological 
disorders by potentially making walking therapy more 
stimulating and engaging as well as more inclusive of a 
range of children. We expect our results to inform fur-
ther research with children with other neurological 
disorders such as acquired brain injury and spinal cord 
injury, in addition to a multi-centre factorial design study 
with children with CP.
The findings of the trial will be disseminated through 
peer-reviewed journals, national and international con-
ferences. Strategies to integrate motor learning principles 
into practice will be communicated to physiotherapists 
through in-person workshops, informed by analysis of 
session content using the MLSRI (Kamath et  al. 2012). 
Upon trial completion, a summary of findings will be 
communicated to participants and families. Intervention 
protocols will be reported in detail, with results reported 
in accordance with CONSORT guidelines.
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